It's likely due to the drug itself having what we call 'weight-independent effects' on cardiovascular events - things like reduced inflammation and improved vasculature and kidney health, all these other beneficial effects that have to do with reducing the development of another cardiovascular event.
Overall, semaglutide reduced participants' risk of mortality from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke by 20 percent.
#obesity #glp-1-receptor-agonist-medications #cardiovascular-disease #semaglutide #health-equity-challenges
[
add
]
[
|
|
...
]